CI Stock Recent News

Wendell Potter, Center for Health and Democracy president and former Cigna vice president, joins 'Squawk Box' to discuss public anger at the health care industry, problems with health insurance, and more.

Cigna (CI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

The healthcare industry, particularly PBMs, faces bipartisan scrutiny, leading to significant stock declines for Humana and Cigna, presenting a contrarian investment opportunity. President-elect Donald Trump's stance on PBMs and bipartisan legislative proposals signal potential regulatory changes, creating market uncertainty for PBM-affiliated companies. Despite recent financial setbacks, Cigna and Humana show strong revenue growth, with investment losses and rising benefit costs impacting short-term profitability.

Barclays analyst Andrew Mok said that while the existential risk to pharmacy benefit managers is low, President-elect Trump's comments yesterday point to additional headline risk and greater support for legislation. Trump said he planned to "knock out the middleman" which is the latest in a string of negative headlines that drove PBM-owned stocks Cigna (CI), CVS Health (CVS) and UnitedHealth (UNH) lower, the analyst told investors yesterday in a research note. The firm believes PBMs "are the only market-based check on drug pricing that exists today," and eliminating the "middleman" would effectively put the government in charge of negotiating drug prices for both private and government-sponsored health plans. Trump, said, "The horrible middleman that makes more money frankly than the drug companies and they don't do anything except they're a middleman, we're going to knock out the middleman." Barclays fact-checked this and notes the average EBIT margins of the top six U.S. pharmaceutic

Shares in major healthcare companies fell yesterday after president-elect Donald Trump made comments that he wanted to “knock out” prescription drug industry middlemen. The fall makes this yet another week since the killing of UnitedHealth CEO Brian Thompson that the business practices of companies that operate America's private healthcare system have come under increased scrutiny.

Cigna's strong fundamentals, including consistent revenue and EPS growth, a solid balance sheet, and undervalued stock price, support a buy rating. The company's Q3 results showed a 29.9% revenue increase and a 10.9% rise in non-GAAP EPS, driven by customer growth and price hikes. Cigna's dividend yield and growth potential are robust, with a low payout ratio and projected double-digit annual EPS growth supporting future dividend increases.

Johnson & Johnson has sued divisions of Cigna , accusing the health insurer of working with a drug-benefit middleman to drain J&J's financial-assistance funds earmarked for patients taking some of its pricier drugs, The Wall Street Journal reported on Friday.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

One influential healthcare analyst says the chances of such a bill passing are less than 5%.

Shares of major healthcare companies fell nearly 5% on Wednesday on concerns related to potential changes to their complex business models. That includes UnitedHealth Group, Cigna and CVS Health, which operate three of the nation's largest private health insurers and drug supply chain middlemen called pharmacy benefit managers.